Tyrosine kinase inhibitorFDA-approvedSecond-line
Regorafenib
How it works
Blocks multiple enzymes involved in cancer cell growth and angiogenesis, starving them of nutrients and oxygen.
Cancer types
Colorectal Cancer— All patients
Efficacy
Studies show that Regorafenib can improve overall survival in patients with metastatic colorectal cancer who have not responded to other treatments.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Combination of Aramchol, Regorafenib, and Metformin Kills Tumor Cells | Melanoma | lab-study | — | Source → |
| Higher Doses of Regorafenib Linked to Improved Survival in Colorectal Cancer | Colorectal Cancer | observational | The median overall survival was 4.6 months for patients who received a cumulative dose of ≤4200 mg and 9.8 months for those who received >4200 mg. | Source → |
| New Combination Treatment Shows Promise for Rare Neuroendocrine Tumors | Pancreatic Cancer | phase-2 | The 6-month objective response rate was 18% (95% confidence interval: 8-31%), with a median progression-free survival of 5.5 months (95% CI: 3.6-8). | Source → |
| Stanniocalcin 1 May Help Predict Outcomes in Colorectal Cancer Patients | Colorectal Cancer | phase-3 | The median overall survival was 7.63 months in the STC1-low group and 3.81 months in the STC1-high group. | Source → |
| Combining cancer drugs shows moderate benefits for colorectal cancer patients | Colorectal Cancer | meta-analysis | The overall response rate was 6% and the median overall survival was 13.08 months. | Source → |
| Combining Chemotherapy and Radiation with Regorafenib in Rectal Cancer | Colorectal Cancer | phase-1 | Among the 19 patients who were treated at the recommended dose, 8 (42.1%) reached the primary endpoint, with 5 (26.3%) having near-complete regression and 3 (15.8%) complete regression. | Source → |
| Researchers Identify Potential Biomarker for Colorectal Cancer Treatment | Colorectal Cancer | phase-2 | — | Source → |
| Regorafenib Dosage May Vary by Body Weight in Colorectal Cancer Patients | Colorectal Cancer | observational | Among the light-weight patients, higher average dose was associated with shorter OS (IPTW adjusted HR=1.21, 95% CI 1.05 - 1.39) | Source → |
| Regorafenib Therapy for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | The median progression-free survival was 4 ± 0.2 months, and the median overall survival was 9 ± 1.2 months. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.